Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.54 CNY based on a 22x P/E ratio for 2026 [5][12]. Core Insights - The company is in a rapid growth phase for its core business and key products over the next 1-2 years, with adjustments made to revenue and expense forecasts [5]. - The first innovative drug, Dazisin, has been approved and is expected to perform well commercially, with significant market potential in the insomnia treatment sector [12][42]. - The company has a strong pipeline focusing on central nervous system and lipid-lowering therapies, with promising products in various stages of development [12][22]. Financial Summary - Revenue projections for the company are as follows: - 2023: 3,999 million CNY - 2024: 4,159 million CNY (growth of 4.0%) - 2025: 4,279 million CNY (growth of 2.9%) - 2026: 4,714 million CNY (growth of 10.2%) - 2027: 5,363 million CNY (growth of 13.8%) [7]. - Net profit attributable to the parent company is projected to grow from 619 million CNY in 2023 to 1,079 million CNY in 2027, reflecting a compound annual growth rate of approximately 17.5% [7]. Business Focus - The company has shifted its focus towards innovation after facing challenges from centralized procurement, with a robust pipeline of generic and innovative drugs [12][15]. - The main therapeutic areas include central nervous system disorders, cardiovascular diseases, and digestive system conditions, with a strong emphasis on innovative drug development [15][19]. Product Pipeline - The company has a diverse pipeline with key products such as: - Dazisin (approved for insomnia) - JX11502 (in Phase II for schizophrenia) - JX2201 (in Phase I for high Lp(a) levels) [23][32]. - The company is also pursuing first-generic opportunities for high-value products, such as Calira, which has significant market potential [27][29]. Market Position - The company has established a solid market presence in the CNS and lipid-lowering sectors, with leading market shares in several key products [24][26]. - The innovative drug Dazisin is positioned to capture a significant share of the insomnia treatment market, which has over 200 million patients in China [42][45].

11月20日，京新药业涨5.22%，截至发稿，报21.36元/股，成交2.74亿元，换手率1.83%，总市值183.92 亿元。 资料显示，浙江京新药业股份有限公司位于浙江省新昌县羽林街道新昌大道东路800号，成立日期1999 年2月13日，上市日期2004年7月15日，公司主营业务涉及化学制剂、传统中药、生物制剂、化学原料 药、医疗器械的研发、生产及销售。主营业务收入构成为：医药制造82.46%，医用器械17.54%。 上银医疗健康混合A（011288）基金经理为杨建楠。 截至发稿，杨建楠累计任职时间3年270天，现任基金资产总规模2.53亿元，任职期间最佳基金回报 4.13%， 任职期间最差基金回报2.97%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，上银基金旗下1只基金重仓京新药业。上银医疗健康混合A（011288）三季度持有股数57.67 万股，占基金净值比例为4.72%，位居第五大重仓股。根据测算，今日 ...

Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 64.25% and a recent decline of 2.01% on November 19, 2023 [1] Financial Performance - For the period from January to September 2025, Jingxin Pharmaceutical reported revenue of 3.048 billion yuan, a year-on-year decrease of 5.00%, while net profit attributable to shareholders was 576 million yuan, reflecting a slight increase of 0.10% [2] - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3] Stock Market Activity - As of November 19, 2023, Jingxin Pharmaceutical's stock price was 20.48 yuan per share, with a total market capitalization of 17.634 billion yuan [1] - The stock has seen significant trading activity, with a net outflow of 1.6599 million yuan from main funds and a notable presence on the "Dragon and Tiger List" on July 4, 2023, where it recorded a net purchase of 1.11 billion yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders for Jingxin Pharmaceutical was 22,300, a decrease of 13.08% from the previous period, while the average circulating shares per person increased by 15.05% to 32,438 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.4588 million shares, a decrease of 2.1904 million shares compared to the previous period [3] Business Overview - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1]

证券之星消息，11月18日化学制药板块较上一交易日下跌0.75%，富祥药业领跌。当日上证指数报收于 3939.81，下跌0.81%。深证成指报收于13080.49，下跌0.92%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002020 | 京新药业 | 20.90 | 7.90% | 48.10万 | 10.02亿 | | 000566 | 因曲與 | 8.00 | 7.38% | 337.76万 | 26.98亿 | | 300086 | 康艺药业 | 11.81 | 6.30% | 146.60万 | 17.58亿 | | 002693 | *ST双成 | 8.46 | 4.96% | 27.04万 | 2.28亿 | | 301507 | 民生健康 | 17.61 | 4.14% | 40.27万 | 7.15亿 | | 688197 | 首药控股 | 41.69 | 2.71% | 1.40万 | 5819.19万 | | 301089 | 拓新药业 ...

11月18日，京新药业涨5.01%，截至发稿，报20.34元/股，成交1.63亿元，换手率1.13%，总市值175.13 亿元。京新药业股价已经连续4天上涨，区间累计涨幅6.02%。 天治新消费混合（350008）基金经理为梁莉。 截至发稿，梁莉累计任职时间4年219天，现任基金资产总规模6431.4万元，任职期间最佳基金回报 29.96%， 任职期间最差基金回报-64.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，浙江京新药业股份有限公司位于浙江省新昌县羽林街道新昌大道东路800号，成立日期1999 年2月13日，上市日期2004年7月15日，公司主营业务涉及化学制剂、传统中药、生物制剂、化学原料 药、医疗器械的研发、生产及销售。主营业务收入构成为：医药制造82.46%，医用器械17.54%。 从基金十大重仓股角度 数据显示，天治基金旗下1只基金重仓京新药业。天治新消费混合（350008）三季度持有股数3.89万 股，占基金净值比 ...

Investment Rating - The report continues to recommend the innovative drug and medical device industry chain, indicating a high level of investment interest in this sector [1][5]. Core Views - The report highlights the high prosperity in innovative drugs, suggesting potential value revaluation for companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [2][5]. - It emphasizes the importance of Biopharma/Biotech companies with innovative pipelines and performance entering a volume increase phase, including Innovent Biologics, BeiGene, and others [2][5]. - The report also points out the recovery potential for leading medical equipment companies like United Imaging Healthcare, Lepu Medical, and others [2][5]. Summary by Sections A-Shares Performance - In the second week of November 2025, the A-Shares pharmaceutical sector outperformed, with the SW Pharmaceutical and Biological index rising by 3.3% while the SHCOMP fell by 0.2% [2][30]. - The pharmaceutical commerce, chemical raw materials, and chemical preparations sub-sectors showed strong performance, with increases of 5.7%, 5.1%, and 4.4% respectively [2][30]. - Notable stock gains included GDK (+61.6%), HPGC Renmintongtai Pharmaceutical Corporation (+61.1%), and Chengda Pharmaceuticals Co., Ltd. (+58.3%) [2][30]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also outperformed, with the Hang Seng Healthcare index increasing by 6.8% and the Hong Kong Biotechnology index by 7.1% [2][31]. - In the U.S., the S&P Healthcare Select Sector rose by 3.9%, significantly outperforming the S&P 500, which only increased by 0.1% [2][32]. Valuation Metrics - As of November 14, 2025, the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 77.0% [2][15]. - The report provides earnings forecasts and valuation metrics for various companies, indicating expected growth rates and price-to-earnings ratios for the coming years [6][7].

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 17, with Shuyatong leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Top Gainers in Chemical Pharmaceutical Sector - Fuxiang Pharmaceutical (300497) saw a closing price of 21.15, with a significant increase of 12.14% and a trading volume of 1.8867 million shares, amounting to a transaction value of 3.8 billion [1] - Muanhai Pharmaceutical (000566) closed at 7.45, up 10.04%, with a trading volume of 2.5684 million shares, totaling 1.871 billion [1] - Kangzhiyue Pharmaceutical (300086) closed at 11.11, increasing by 4.61%, with a trading volume of 1.5735 million shares, amounting to 1.747 billion [1] Top Losers in Chemical Pharmaceutical Sector - Buzou Pharmaceutical (300204) closed at 36.31, down 7.61%, with a trading volume of 560,200 shares, resulting in a transaction value of 2.067 billion [2] - Anglikang (002940) closed at 43.43, decreasing by 7.60%, with a trading volume of 251,600 shares, totaling 1.112 billion [2] - Aozhu Pharmaceutical (002755) closed at 18.59, down 5.59%, with a trading volume of 260,100 shares, amounting to 489 million [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 3.72 billion from institutional investors, while retail investors saw a net inflow of 2.604 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Jingxin Pharmaceutical (002020) had a net inflow of 21.78 million from institutional investors, while retail investors experienced a net outflow of 13.49 million [3] - Taiankang (301263) saw a net inflow of 13.83 million from institutional investors, with retail investors facing a net outflow of 26.79 million [3] - Meinuohua (603538) recorded a net inflow of 12.13 million from institutional investors, while retail investors had a net outflow of 17.35 million [3]

Investment Rating - The report does not explicitly state an investment rating for the antidepressant drug industry Core Insights - Depression disorders are the most common mental disorders, characterized by persistent low mood, loss of pleasure, and decreased energy. The etiology remains unclear, with various hypotheses including the monoamine hypothesis and glutamatergic system abnormalities [5][23] - There are unmet clinical needs in depression treatment, including limited efficacy of current first-line antidepressants, slow onset of action, and the need for precision treatment for different subtypes and special populations [5][27] - The current market for antidepressants in China is substantial, with over 8 billion yuan in hospital sales, where SSRIs and SNRIs account for approximately 60% of the market share [5][6] - New drug development is focusing on deepening monoamine research, exploring amino acid classes, and other mechanisms, with a gradual entry into a harvest period for innovative drugs [5][6] Summary by Sections Unmet Clinical Needs - Current first-line antidepressants like SSRIs have limited efficacy, with about one-third of patients not achieving remission after multiple treatment steps [27] - The onset of current antidepressants is slow, typically requiring 1-4 weeks for initial improvement and 4-8 weeks to reach treatment goals, posing risks for patients during acute phases [27][28] - There is a need for precision treatment for different subtypes of depression and special populations such as children and the elderly [27] Market Overview - The antidepressant market in China saw over 8 billion yuan in sales, with SSRIs leading at 3.58 billion yuan (43.44% market share) and SNRIs at 1.42 billion yuan (17.18% market share) [5][6] - The top-selling antidepressants include escitalopram oxalate, agomelatine, and sertraline [5] Drug Development Trends - The report highlights ongoing research into monoamine neurotransmitter drugs, with 128 clinical-stage products targeting various mechanisms [5][6] - Innovative drugs are gradually entering the market, with one local innovative drug already launched and over twenty in clinical trials [5][6]

Group 1 - In October, A-share listed companies continued to implement share buyback plans, with companies like Aibijungguang, Jiuan Medical, COSCO Shipping Holdings, Fujilai, and Minsheng Health announcing their second buyback plans of the year, while Zhijiang Biology launched its third buyback plan for the year, indicating a strategic approach to long-term market value management [1] - Jiuan Medical has been actively maintaining its market value through share buybacks, having executed five buyback plans since 2021, with a total expenditure of 2.879 billion yuan (including some transaction costs) and a cumulative repurchase of 94.9214 million shares [1] - As of the end of October, approximately 348 companies that are currently implementing buybacks have disclosed their progress, with around 137 companies meeting the lower limit of their buyback plans, indicating a relatively fast overall pace [1] Group 2 - Midea Group's buyback efforts have exceeded expectations, with a single-month buyback of 2.466 billion yuan in October, marking the second consecutive month of over 2 billion yuan in buybacks, bringing the total for the year close to 10 billion yuan, making it one of the most active companies in the A-share market for buybacks [2] - Other companies with significant buyback amounts in October include GoerTek, Runze Technology, Youngor, Hengrui Medicine, SF Holding, and Chengde Lululemon, with buyback amounts of 430 million yuan, 351 million yuan, 229 million yuan, 220 million yuan, 200 million yuan, and 153 million yuan respectively [2] - Companies with the highest cumulative buyback ratios as of the end of October include Kejie Intelligent, Huamao Technology, Jingxin Pharmaceutical, and Zhezhong Co., with ratios of 6.66%, 6.42%, 5.49%, and 5% respectively [2]

Core Insights - Jingxin Pharmaceutical has achieved hospital coverage of over 1,500 for its drug Didasanib in the first half of the year, indicating a strong market presence and ongoing efforts to enhance patient accessibility [2] Company Summary - The company is actively promoting the hospital admission of Didasanib, which reflects its commitment to improving patient access to this medication [2]